SWOG clinical trial number
CTSU/A021202

Prospective Randomized Phase II Trial of Pazopanib (NSC #737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors

Closed
Phase
II
Abbreviated Title
Rando Pazopanib vs Placebo in Progressive Carcinoid
Status Notes
Closed to accrual effective 10/7/16.
Activated
01/15/2014
Closed
10/07/2016
Participants
CTSU

Research committees

Gastrointestinal Cancer

Treatment

Pazopanib Placebo

Publication Information Expand/Collapse

2021

Discordance between central vs. local response assessments in neuroendocrine tumor (NET) patients enrolled in A021202

S Geyer;M Mahoney;T Asmis;N Hall;S Karovic;M Knopp;P Kumthekar;A Nixon;E O'Reilly;L Schwartz;J Strosberg;J Meyerhardt;M Maitland;E Bergsland J Clin Oncol 39, 2021 (suppl 3; abstr 361); ASCO GI Cancers Symposium (January 15-17, 2021, virtual)

2020

New strategies to improve drug development in carcinoid tumors (Alliance A021202)

E Bergsland;S Geyer;M Mahoney;T Asmis;N Hall;S Karovic;M Knopp;P Kumthekar;A Nixon;E OReilly;L Schwartz;J Strosberg;J Meyerhardt;M Maitland Neuroendocrine Tumor Research Foundation Research Symposium (November 2020), poster

2019

Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202)

E Bergsland;M Mahoney;T Asmis;N Hall;P Kumthekar;M Maitland;D Niedzwiecki;AB Nixon;EM O'Reilly;LH Schwartz;JA Sloan;J Strosberg;J Meyerhardt J Clin Oncol 37(suppl; abstr 4005); American Society of Clinical Oncology (5/31 - 6/4/2019, Chicago IL), oral

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA2176
SWOG Clinical Trial Number
CTSU/A021806

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Research Committee(s)
Gastrointestinal Cancer
Activated
07/01/2020
Open